Physician profile
Kaylee Mahoney
NPI 1356873095
$6,784.44
in general payments reported to CMS, 2019-2025
26 companies · $3,308 in 2025
The $3,308 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,325 · 2023: $1,117 · 2024: $1,034 · 2025: $3,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059 · Consulting Fee: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.97 |
| Consulting Fee | $2,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Srs Medical Systems, INC. | $2,423.51 | 2024-2025 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Teleflex LLC | $1,952.61 | 2022-2024 | Urolift |
| Sumitomo Pharma America, INC. | $455.28 | 2023-2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $310.00 | 2023-2025 | Aquabeam Robotic System |
| Abbvie INC. | $309.61 | 2023-2025 | |
| Coloplast Corp | $179.60 | 2025 | |
| Merck Sharp & Dohme LLC | $177.22 | 2023-2024 | Keytruda, Lynparza |
| Dendreon Pharmaceuticals LLC | $153.28 | 2022-2025 | Provenge |
| Urogen Pharma, INC. | $152.26 | 2023-2025 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $107.14 | 2022-2024 | |
| Janssen Biotech, INC. | $92.73 | 2024-2025 | Erleada |
| Olympus America INC. | $85.44 | 2025 | Itind System |
| Boston Scientific Corporation | $60.08 | 2022-2023 | |
| Laborie Medical Technologies Corp. | $52.99 | 2025 | |
| Progenics Pharmaceuticals, INC. | $46.59 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $38.43 | 2023 | |
| Pfizer INC. | $35.41 | 2024 | |
| Tolmar, INC. | $21.66 | 2023 | |
| Antares Pharma, INC. | $21.30 | 2023 | Nocdurna, Tlando, Xyosted |
| Hollister Incorporated | $19.82 | 2023 | Infyna Chic |
| Ferring Pharmaceuticals INC. | $17.15 | 2024 | Adstiladrin |
| Genzyme Corporation | $15.98 | 2022 | |
| Myovant Sciences INC. | $15.23 | 2022 | |
| Sun Pharmaceutical Industries INC. | $14.10 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.70 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $13.32 | 2024 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylee Mahoney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.